A trial of PSMA-targeted thorium-227 conjugate in patients with Metastatic Castration-resistant Prostate cancer (mCRPC).
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2018
At a glance
- Drugs Thorium-227 radiolabelled antibodies (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 08 Mar 2018 According to a Bayer media release, this trial is expected to initiate by year end 2018.
- 06 Dec 2017 New trial record
- 01 Dec 2017 According to a Bayer media release, this trial is expected to initiate in 2018.